Information for Physicians

Technical details, ordering process and scientific evidence for our liquid biopsy tests

Test Specifications

Ordering Process

Clinical Evidence

Forms & Downloads
Tests

Vista ctDNA Test Family - Technical Specifications

LymphoVista - B-Cell Lymphomas

Technical Validation of Genotyping: In a technical validation study: 93.86% sensitivity, 99.999% specificity for variant detection at variants ≥0.5% mAF 1
MRD Detection: LoD 6.69 × 10⁻⁶, 100% accuracy for MRD >3.04 × 10⁻⁵ 1
Sample Material: 20ml blood in specialized cfDNA tubes. We are happy to provide our collection kits with tubes, all necessary documents and a blood collection system. Simply contact us. Link to contact form
Turnaround Time: 2-4 weeks
Status: In-house IVD

LymphoVista HL - Hodgkin Lymphoma

Technical Validation of Genotyping: 91.27% sensitivity, 99.99% specificity for variants ≥0.5% mAF
MRD Detection: LoD 6.54 × 10⁻⁶, 100% accuracy for MRD >1.76 × 10⁻⁵
Sample Material: 20ml blood in specialized cfDNA tubes. We are happy to provide our collection kits with tubes, all necessary documents and a blood collection system. Simply contact us. Link to contact form
Turnaround Time: 2-4 weeks
Status: In-house IVD

CancerVista - Solid Tumors

Status: In development for lung cancer, breast cancer, colorectal cancer, prostate cancer
Currently: Available for research use only (RUO)
Technology: Same Vista platform with tumor-specific panels
Status: RUO available
Evidence

Clinical Performance Data

LymphoVista - Large B-Cell Lymphoma

Our technology was clinically validated in relapsed large B-cell lymphoma with 326 samples from 88 patients across 131 treatment lines.

18-month OS: 77% (MRD-negative) vs. 33% (MRD-positive), HR 4.61, p<0.0001 2
18-month PFS: 51% (MRD-negative) vs. 5% (MRD-positive), HR 4.32, p<0.0001 2

LymphoVista HL - Hodgkin Lymphoma (HD21 Study)

Our technology was clinically validated in advanced newly diagnosed Hodgkin lymphoma with a median follow-up of 50 months.

MRD-2-positive rate: 18.5% after 2 chemotherapy cycles
4-year PFS: 95.3% vs. 72.2% (MRD-2-negative vs. -positive), HR 6.9, p<0.0001 1

For more detailed information on both studies and the corresponding survival curves, please visit our LymphoVista page.

Ordering

Ordering Process

1

Registration

Contact us for further information, registration and to receive free collection kits Link to contact form

2

Test Request

Fill out the request form and select the desired test

3

Sample Collection

Collect 20ml of blood as specified in the kit

4

Report

You will receive the report after 2-4 weeks via password-protected email

Science

Clinical Evidence

Scientific Validation

We are happy to provide detailed study data and scientific evidence upon request.

Get in Touch

Referenzen

1 Mattlener et al. Presentation at American Society of Hematology (ASH) Annual Meeting 2024

2 Schleifenbaum et al. Presentation at European Hematology Association (EHA) Annual Meeting 2024

Downloads

Formulare & Downloads

Anforderungsformular

Formular zur Testanforderung

Zu den Downloads

Produktbroschüre

Detaillierte Produktinformationen

Zu den Downloads

Newsletter-Anmeldung

Newsletter-Anmeldung erfolgreich!

Danke für Ihre Anmeldung! Sie erhalten eine Bestätigungs-E-Mail.